A phase III trial to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode

Trial Profile

A phase III trial to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Bipolar I disorders; Schizophrenia
  • Focus Adverse reactions
  • Acronyms APEX 241
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jan 2009 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 08 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top